Life Sciences Tools & Services · NYSE
CRLCharles River Laboratories International, Inc.
- Last close
- $337.97 -0.8%
- 52-week range
- $146.19 to $379.63
- Market cap
- $16.2B
- Next earnings
- Not scheduled
Fiscal 2025 at a glance
Stock price
Valuation vs its own 10 years
Above its 10-year median on all 4 multiples
Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-26. Every figure carries its unit.
Valuation
- P/E
- 399x
- Earnings yield
- 0.3%
- Price / sales
- 4.1x
- Price / book
- 5.0x
- Price / operating cash flow
- 26.0x
- EV / EBITDA
- 41.5x
- EV / sales
- 4.6x
- Free cash flow yield
- 2.5%
Profitability
- Gross margin
- n/aNot reported
- Operating margin
- 4.0%
- Net margin
- 1.0%
- Return on equity
- 1.2%
- Return on capital
- 2.2%
Growth per year
- Revenue, 3 years
- +0.3%
- Revenue, 5 years
- +6.5%
- Revenue, 9 years
- +10.2%
- EPS, 3 years
- n/aNot meaningful (a loss in the window)
Balance sheet
- Cash and investments
- $200M
- Total debt
- $2.45B
- Net cash
- -$2.25B
- Debt / equity
- 0.76x
- Current ratio
- 1.41x
Shares and dividend
- Shares outstanding
- 47.9M
- Share count, 5 years
- -2.1%
- Beta, 1 year
- 1.27
- Dividend yield
- n/a
- Dividend per share, TTM
- n/a
- Payout ratio
- n/a
n/a: No dividend
Ten years of the business
Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.
Fiscal years 2016 to 2025.
Where the revenue comes from
Product went from 19% to 19% of revenue in 3 years
Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.
| Product line | Revenue | Share | vs FY24 |
|---|---|---|---|
| Services | $3.25B | 80.9% | -2% |
| Product | $765M | 19.1% | +3% |
Life Sciences Tools & Services peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | $259B | +8% | 17.9% | 36.9x | 5.5x | 88th percentile |
| A Agilent Technologies, Inc. | $49.0B | +9% | 22.2% | 34.2x | 6.7x | 64th percentile |
| WAT Waters Corp | $45.2B | +81% | 4.7% | 198x | 8.1x | 90th percentile |
| IQV Iqvia Holdings Inc. | $43.7B | +9% | 12.8% | 32.2x | 2.5x | 38th percentile |
| MTD Mettler Toledo International Inc/ | $34.6B | +7% | n/a | 37.7x | 8.2x | 58th percentile |
| CRL Charles River Laboratories International, Inc. | $16.2B | -1% | 4.0% | 399x | 4.1x | 97th percentile |
The company
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Founded
- 1947
- Headquarters
- Wilmington, MA
- Fiscal year ends
- Late December
- Website
- criver.com
What it does
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics.
Description from Wikipedia (CC BY-SA).
Around the numbers
What the rest of EdgeStacker knows about CRL.